Maia Biotechnology Signs Stock Purchase Agreement with Prevail Partners for Phase 3 Cancer Study Funding
MAIA Biotechnology, Inc. has entered into a significant stock purchase agreement with Prevail Partners, LLC, involving the issuance and sale of $587,905 worth of its common stock. The agreement, signed on June 24, 2025, includes an upfront payment of $58,800.3333 in shares and 36 equal tranche payments of $14,697.333 each. The stock will be sold at a minimum share price of $1.74, with a maximum issuance of 337,876 shares, adhering to a 19.99% issuance cap. The proceeds from this agreement will be used to fund technologies and services provided by Prevail Infoworks under a previously established Master Service and Technology Agreement. These services are crucial for a Phase 3 study evaluating THIO in combination with cemiplimab versus chemotherapy for advanced non-small cell lung cancer treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-016574), on June 26, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。